Memorial Sloan Kettering, The Rockefeller University, and Weill Cornell Medical College have announced that they have formed the pioneering Tri-Institutional Therapeutics Discovery Institute, Inc. and have partnered with Takeda Pharmaceutical Company, Ltd.
The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) is a unique partnership among Weill Cornell Medical College, Memorial Sloan Kettering and Rockefeller University. Tri-I TDI has entered into an initial partnership with Takeda Pharmaceuticals to assist academic investigators at the three institutions to develop small molecule therapeutic agents and molecular probes. While Tri-I TDI will initially focus on the development of small molecules, Tri-I TDI plans to expand over time to include biologic agents, especially monoclonal antibodies, and molecular imaging agents.
The concept, goals, and structure of Tri-I TDI have been under study and discussion for more than 30 months, including site visits to other programs and analysis of other academic-industry partnerships. Ultimately, there was a consensus that Tri-I TDI could best achieve its goals by being organized as a non-profit corporation that integrates the resources of the three academic partners and forms collaborations as needed with pharmaceutical companies and biotech companies. The first of these is with Takeda, which has extraordinary strengths in medicinal chemistry.